Pancreatic Cancer Research

ResearcherNational Cancer CenterActive in the last 2 years

Sang‐Jae Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5582-9420; OpenAlex author ID A5002240113. Sources: OpenAlex.

Their work

Papers
38 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
92
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 3 papers · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 5 papers · 2019: 5 papers · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 5 papers · 2024: 3 papers · 2025: 4 papers

Papers 38

  1. Increased diagnosis of hepato-biliary-pancreatic cancer after cholecystectomy: a population-based study. Last author DOI 10.1038/s41598-024-84781-7↗
  2. Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicente… Co-author DOI 10.1093/clinchem/hvaf066↗
  3. Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC. Co-author DOI 10.3390/cancers17182988↗
  4. Epidemiology and survival analysis according to the histologic subtype of pancreatic cancer: a population-based cohort study. Co-author DOI 10.4174/astr.2025.108.1.20↗
  5. New Function Annotation of PROSER2 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acs.jproteome.3c00632↗
  6. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Co-author DOI 10.1111/cas.16104↗
  7. Conditional Relative Survival of Exocrine Pancreatic Cancer: A Population-Based Study. Co-author DOI 10.1245/s10434-023-14594-x↗
  8. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  9. Exocrine pancreatic cancer as a second primary malignancy: A population-based study. Co-author DOI 10.14701/ahbps.23-053↗
  10. Exploring Connections between Oral Microbiota, Short-Chain Fatty Acids, and Specific Cancer Types: A Study of Oral Cancer, Head and Neck Cancer, Pancreatic Can… Co-author DOI 10.3390/cancers15112898↗
  11. 15-Year Experience of Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer-A Korean Nationwide Investigation. First author DOI 10.3390/cancers15153850↗
  12. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2023.291↗
  13. Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019. Last author DOI 10.14701/ahbps.22-041↗
  14. Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea. Co-author DOI 10.3346/jkms.2022.37.e216↗
  15. First Course of treatment and Prognosis of Exocrine Pancreatic Cancer in Korea from 2006 to 2017. Co-author DOI 10.4143/crt.2021.421↗
  16. Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study. Co-author DOI 10.3390/cancers13215466↗
  17. Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Resul… Co-author DOI 10.5009/gnl20306↗
  18. Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. Co-author DOI 10.1038/s41598-020-78875-1↗
  19. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2019.06.002↗
  20. Cytopathological results of initial endoscopic ultrasound-guided fine needle aspiration for primary mass and prognosis in pancreatic cancer patients. Co-author DOI 10.1111/cyt.12675↗
  21. Surgery for elderly patients with resectable pancreatic cancer, a comparison with non-surgical treatments: a retrospective study outcomes of resectable pancrea… First author DOI 10.1186/s12885-019-6255-3↗
  22. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Sam… Co-author DOI 10.3389/fonc.2019.00875↗
  23. Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuva… Last author DOI 10.5009/gnl18355↗
  24. Favorable glycemic response after pancreatoduodenectomy in both patients with pancreatic cancer and patients with non-pancreatic cancer. Last author DOI 10.1097/md.0000000000010590↗
  25. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospect… Co-author DOI 10.1097/sla.0000000000002705↗
  26. Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer. Co-author DOI 10.1177/1533033818783879↗
  27. Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1373/clinchem.2017.283721↗
  28. Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction c… Co-author DOI 10.3857/roj.2018.00073↗
  29. Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine fo… Co-author DOI 10.4143/crt.2016.495↗
  30. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Co-author DOI 10.1016/j.pan.2016.09.001↗
  31. Development and Validation of a Prediction Model to Estimate Individual Risk of Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0146473↗
  32. Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1186/1748-717x-8-160↗
  33. Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case-control study. Co-author DOI 10.3346/jkms.2013.28.2.247↗
  34. Changes in dietary intake, body weight, nutritional status, and metabolic rate in a pancreatic cancer patient. Co-author DOI 10.7762/cnr.2013.2.2.154↗
  35. Multiple primary malignant neoplasms in pancreatic cancer patients: a single-center experience in Korea. Co-author DOI 10.1097/mpa.0b013e3182374d65↗
  36. CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2010.10.011↗
  37. Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and u… Co-author DOI 10.1016/j.ijrobp.2011.02.063↗
  38. Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET. Co-author DOI 10.1097/rlu.0b013e31820a9eea↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sung‐Sik Han · 29 shared papers, 2011–2025 · strength 3.54
  2. Sang Myung Woo · 25 shared papers, 2011–2025 · strength 2.40
  3. Woo Jin Lee · 23 shared papers, 2011–2025 · strength 2.02
  4. Hyeong Min Park · 8 shared papers, 2019–2025 · strength 1.80
  5. Mee Joo Kang · 7 shared papers, 2022–2025 · strength 1.66
  6. Yun‐Hee Kim · 10 shared papers, 2016–2025 · strength 1.25
  7. Sun‐Young Kong · 9 shared papers, 2017–2025 · strength 1.20
  8. Kyu‐Won Jung · 4 shared papers, 2022–2025 · strength 0.98
  9. Jung Won Chun · 4 shared papers, 2023–2025 · strength 0.80
  10. Min Kyeong Kim · 6 shared papers, 2017–2025 · strength 0.73
  11. Tae Hyun Kim · 12 shared papers, 2011–2020 · strength 0.71
  12. Kyong‐Ah Yoon · 6 shared papers, 2017–2024 · strength 0.61
  13. Sun‐Whe Kim · 4 shared papers, 2018–2023 · strength 0.60
  14. Young‐Joo Won · 3 shared papers, 2022–2023 · strength 0.54
  15. Yoo‐Seok Yoon · 4 shared papers, 2019–2023 · strength 0.48
  16. Eun Kyung Hong · 9 shared papers, 2011–2019 · strength 0.48
  17. Jin Seok Heo · 4 shared papers, 2018–2023 · strength 0.46
  18. Jin‐Young Jang · 4 shared papers, 2018–2023 · strength 0.46
  19. Jin‐Hyeok Hwang · 3 shared papers, 2019–2025 · strength 0.41
  20. In Woong Han · 3 shared papers, 2021–2023 · strength 0.40
  21. Dae Yong Kim · 6 shared papers, 2011–2020 · strength 0.34
  22. Young Ae Kim · 1 shared paper, 2025 · strength 0.30
  23. Yu‐Sun Lee · 2 shared papers, 2019–2024 · strength 0.28
  24. Wooil Kwon · 3 shared papers, 2018–2023 · strength 0.28
  25. Dae Wook Hwang · 2 shared papers, 2021–2023 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.